|
|
Article: Nausea Taints ConjuChem's Diabetes Drug Phase II Trial.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
While DAC:GLP-1 hit its primary endpoint as a diabetes monotherapy in a Phase II trial that evaluated it in four doses, the drug's nausea and vomiting side effects sent ConjuChem's stock tumbling.
The Montreal-based company watched its shares (TSE:CJC) drop C$5.45 Thursday, or 53.2 percent, to close at C$4.80 They rose 80 cents Friday to close at C$5.60 (US$4.27).
"There are nervous investors," said Jacques Lapointe, chairman, president and CEO of ConjuChem. "There were some high expectations from the trial. We certainly met and exceeded the efficacy expectations. But we certainly fell short on the nausea expectations."
...